• Institute for Clinical Systems Improvement (ICSI). Menopause and hormone therapy (HT): collaborative decision-making and management. Bloomington (MN): Institute for Clinical Systems Improvement (ICSI); 2008 Oct. 64 p. [198 references]

Does not apply to this measure

This measure is used to assess the percentage of women in menopause who have had a bone mineral density (BMD) measurement a year after cessation of hormone therapy (HT).

The priority aim addressed by this measure is to increase the percentage of women with appropriate follow-up to cessation of hormone therapy (HT).

Menopause; hormone therapy (HT); bone mineral density (BMD) measurement

Total number of women in the medical group's practice in menopause who have discontinued hormone therapy (HT) (see the related "Denominator Inclusions/Exclusions" field in the Complete Summary)

Number of women in menopause receiving a bone mineral density (BMD) measurement a year after cessation of hormone therapy (HT)

• A clinical practice guideline or other peer-reviewed synthesis of the clinical evidence

Unspecified

Current routine use

Internal quality improvement

Physician Group Practices/Clinics

Physicians

Group Clinical Practices

Unspecified

Female (only)

Unspecified

More women than ever before will be entering menopause as the "baby boomer" generation ages. By the year 2020, the number of perimenopausal women will almost double to 40 million.

• Institute for Clinical Systems Improvement (ICSI). Menopause and hormone therapy (HT): collaborative decision-making and management. Bloomington (MN): Institute for Clinical Systems Improvement (ICSI); 2008 Oct. 64 p. [198 references]

Unspecified

Unspecified

Unspecified

Unspecified

Living with Illness

Effectiveness

Users of care only

Women who are in menopause and have discontinued hormone therapy (HT)

Select a randomized sample of the eligible population for data collection. The suggested sample size for each medical group is at least 10 charts each month.

The medical record of each woman is reviewed to determine if the woman is in menopause and had discontinued HT.

The suggested time frame for data collection is a calendar month.

Patients associated with provider

Inclusions
Total number of women in the medical group's practice* in menopause** who have discontinued hormone therapy (HT)

*"In the medical group practice" is defined as a woman who has been seen two or more times by the medical group (including office visits and urgent care).

**A woman is diagnosed as having menopause if 1) she has had complete cessation of menses for one year, 2) premature menopause, or 3) surgical-, chemotherapy-, or radiation-induced menopause, or 4) if younger than average, or continuation of regular menses, and has a positive follicle stimulating hormone (FSH) and/or estradiol lab test. This would correspond to patients with diagnosis codes V49.81, 256.31, 256.2 and 627.x and Current Procedure Terminology (CPT) codes 80418, 80426, and/or 82670.

Exclusions
Unspecified

All cases in the denominator are equally eligible to appear in the numerator

Clinical Condition

Time window is a single point in time

Inclusions
Number of women in menopause receiving a bone mineral density (BMD) measurement a year after cessation of hormone therapy (HT)

Exclusions
Unspecified

The measure results are somewhat or substantially under the control of the health care professionals, organizations and/or policymakers to whom the measure applies.

Episode of care

Administrative data
Medical record

Individual Case

Unspecified

Rate

Better quality is associated with a higher score

Unspecified

Internal time comparison

Unspecified

The percentage of women in menopause who have had a bone mineral density (BMD) measurement a year after cessation of HT.

Institute for Clinical Systems Improvement

The following Minnesota health plans provide direct financial support: Blue Cross and Blue Shield of Minnesota, HealthPartners, Medica, Metropolitan Health Plan, PreferredOne and UCare Minnesota. In-kind support is provided by the Institute for Clinical Systems Improvement's (ICSI) members.

Work Group Members: John M. Wilkinson, MD (Work Group Leader) (Mayo Clinic) (Family Medicine); Mary Amon, MD (Family Practice Medical Center) (Family Medicine); Donald Deye, MD (Allina Medical Clinic) (Internal Medicine); Dale Akkerman, MD (Park Nicollet Health Services) (Ob/Gyn); Andrew Good, MD (Mayo Clinic) (Ob/Gyn); Richard Kopher, MD (HealthPartners Medical Group) (Ob/Gyn); June LaValleur, MD (University of Minnesota Physicians) (Ob/Gyn); Jodi A. Chaffin, RPh (HealthPartners Medical Group) (Herbal Resource Pharmacist) (Pharmacy); Sharon MacDonald (Patient Representative); Sylvia Robinson, BSN, MBA (Institute for Clinical Systems Improvement) (Implementation/Measurement Advisor); Linda Setterlund, MA (Institute for Clinical Systems Improvement) (Facilitator)

Measure was not adapted from another source.

2004 Oct

2008 Oct

This is the current release of the measure.

This measure updates a previous version: Institute for Clinical Systems Improvement (ICSI). Menopause and hormone therapy (HT): collaborative decision-making and management. Bloomington (MN): Institute for Clinical Systems Improvement (ICSI); 2006 Oct. 63 p.

• Institute for Clinical Systems Improvement (ICSI). Menopause and hormone therapy (HT): collaborative decision-making and management. Bloomington (MN): Institute for Clinical Systems Improvement (ICSI); 2008 Oct. 64 p. [198 references]

This NQMC summary was completed by ECRI on January 19, 2005. This NQMC summary was updated by ECRI Institute on October 25, 2005, December 11, 2006, and again on November 26, 2008.

This NQMC summary (abstracted Institute for Clinical Systems Improvement [ICSI] Measure) is based on the original measure, which is subject to the measure developer's copyright restrictions.

The abstracted ICSI Measures contained in this Web site may be downloaded by any individual or organization. If the abstracted ICSI Measures are downloaded by an individual, the individual may not distribute copies to third parties.

If the abstracted ICSI Measures are downloaded by an organization, copies may be distributed to the organization's employees but may not be distributed outside of the organization without the prior written consent of the Institute for Clinical Systems Improvement, Inc.

All other copyright rights in the abstracted ICSI Measures are reserved by the Institute for Clinical Systems Improvement, Inc. The Institute for Clinical Systems Improvement, Inc. assumes no liability for any adaptations or revisions or modifications made to the abstracts of the ICSI Measures.